JP2007514662A5 - - Google Patents

Download PDF

Info

Publication number
JP2007514662A5
JP2007514662A5 JP2006541552A JP2006541552A JP2007514662A5 JP 2007514662 A5 JP2007514662 A5 JP 2007514662A5 JP 2006541552 A JP2006541552 A JP 2006541552A JP 2006541552 A JP2006541552 A JP 2006541552A JP 2007514662 A5 JP2007514662 A5 JP 2007514662A5
Authority
JP
Japan
Prior art keywords
ylene
phen
alkyl
nhc
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006541552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514662A (ja
JP4851937B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/038975 external-priority patent/WO2005051946A2/en
Publication of JP2007514662A publication Critical patent/JP2007514662A/ja
Publication of JP2007514662A5 publication Critical patent/JP2007514662A5/ja
Application granted granted Critical
Publication of JP4851937B2 publication Critical patent/JP4851937B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006541552A 2003-11-21 2004-11-19 β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 Expired - Fee Related JP4851937B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52423403P 2003-11-21 2003-11-21
US60/524,234 2003-11-21
PCT/US2004/038975 WO2005051946A2 (en) 2003-11-21 2004-11-19 Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011121065A Division JP2011190271A (ja) 2003-11-21 2011-05-30 β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物

Publications (3)

Publication Number Publication Date
JP2007514662A JP2007514662A (ja) 2007-06-07
JP2007514662A5 true JP2007514662A5 (https=) 2007-12-06
JP4851937B2 JP4851937B2 (ja) 2012-01-11

Family

ID=34632881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006541552A Expired - Fee Related JP4851937B2 (ja) 2003-11-21 2004-11-19 β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
JP2011121065A Withdrawn JP2011190271A (ja) 2003-11-21 2011-05-30 β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011121065A Withdrawn JP2011190271A (ja) 2003-11-21 2011-05-30 β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物

Country Status (9)

Country Link
US (4) US7345060B2 (https=)
EP (1) EP1685118B1 (https=)
JP (2) JP4851937B2 (https=)
CN (1) CN100569760C (https=)
AT (1) ATE435855T1 (https=)
CA (1) CA2543858C (https=)
DE (1) DE602004021959D1 (https=)
ES (1) ES2329586T3 (https=)
WO (1) WO2005051946A2 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
PE20050711A1 (es) * 2003-07-17 2005-09-10 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
TW200523261A (en) * 2003-07-17 2005-07-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
WO2005037280A1 (en) * 2003-10-14 2005-04-28 Glaxo Group Limited Muscarinic acetycholine receptor antagonists
AU2004281167A1 (en) * 2003-10-17 2005-04-28 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists field of the invention
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528413A (ja) * 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
WO2005087737A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723112A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7265133B2 (en) * 2004-03-11 2007-09-04 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723110A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2008537931A (ja) * 2005-03-10 2008-10-02 セラヴァンス, インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008538104A (ja) * 2005-03-10 2008-10-09 セラヴァンス, インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
WO2006099032A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008546695A (ja) * 2005-06-13 2008-12-25 セラヴァンス, インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
US20080234315A1 (en) * 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
JP5540075B2 (ja) * 2009-04-14 2014-07-02 グラクソ グループ リミテッド ビフェニル−2−イルカルバミン酸エステルの調製方法
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
GB0913342D0 (en) * 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
KR101742253B1 (ko) 2010-07-13 2017-05-31 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 비페닐-2-일카르밤산의 제조방법
WO2012032546A2 (en) * 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
ME02297B (me) 2011-06-10 2016-02-20 Chiesi Farm Spa Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
BR112013030302B1 (pt) 2011-06-10 2021-08-24 Chiesi Farmaceutici S.P.A. Composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
AR093832A1 (es) 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
BR112015012730B1 (pt) 2012-12-06 2022-07-05 Chiesi Farmaceutici S.P.A. Composto, composição farmaceutica, dispositivo, uso de um composto e combinação
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2017114377A1 (zh) * 2015-12-29 2017-07-06 四川海思科制药有限公司 一种苯基杂环衍生物及其在医药上的用途
BR112018015018A2 (pt) * 2016-01-22 2018-12-18 Sichuan Haisco Pharmaceutical Co Ltd derivado de amido azaciclo, método de preparação deste, e aplicação farmacêutica
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
RU2722720C1 (ru) 2016-12-14 2020-06-03 Бейджинг Шоубай Фармасьютикэл Ко., Лтд. Класс бифункциональных соединений со структурой соли четвертичного аммония
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
WO2019015639A1 (zh) * 2017-07-21 2019-01-24 四川海思科制药有限公司 一种氮杂环酰胺衍生物组合物及其制备
WO2019015640A1 (zh) * 2017-07-21 2019-01-24 四川海思科制药有限公司 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
CN115093365B (zh) * 2022-07-25 2023-07-25 沈阳药科大学 一种雷芬那辛的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181802A (en) 1978-05-11 1980-01-01 Janssen Pharmaceutica N.V. 1-(Heterocyclylalkyl)-1,3-dihydro-2-H-benzimidazole-2-ones
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
US5648370A (en) 1990-11-20 1997-07-15 Astra Pharmaceuticals Limited 7-(2-aminoethyl) benzothiazolones
GB9211172D0 (en) 1992-05-27 1992-07-08 Fisons Plc Compounds
GB9210632D0 (en) 1992-05-19 1992-07-01 Fisons Plc Compounds
IE914003A1 (en) 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
CA2133083A1 (en) 1992-03-31 1993-10-14 Alexander W. Oxford Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht antagonists
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
TW356468B (en) 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
GB9526511D0 (en) 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
WO1999009018A1 (en) 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY
CA2313125A1 (en) 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
WO1999064043A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Muscarinic receptor antagonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
SE9900693D0 (sv) 1999-02-26 1999-02-26 Astra Pharma Prod Novel process
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
SE9902936D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902938D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902937D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
DE60021282T2 (de) 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7094790B2 (en) * 2003-05-07 2006-08-22 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.

Similar Documents

Publication Publication Date Title
JP2007514662A5 (https=)
JP2007501862A5 (https=)
JP2008510015A5 (https=)
JP2006522134A5 (https=)
JP2008510014A5 (https=)
JP4851937B2 (ja) β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
RU2015101032A (ru) ДИАМИДНЫЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ АНТАГОНИСТА МУСКАРИНОВОГО РЕЦЕПТОРА И АКТИВНОСТЬЮ АГОНИСТА β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
RU2388465C2 (ru) Комбинации гликопирролата и агонистов в-2 адреноцептора
JPWO2003020313A1 (ja) スフィンゴシン−1−リン酸受容体調節剤からなる呼吸器疾患治療剤
RU2008146383A (ru) ДИАЛКИЛФЕНИЛЬНЫЕ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МУСКАРИНОВЫХ РЕЦЕПТОРОВ
RU2009104764A (ru) Производные пурина, как антангонисты a2a
JP2018172387A5 (https=)
EP1613321A2 (en) Muscarinic m1 receptor agonists for pain management
JP4582456B2 (ja) 8−アザプロスタグランジン誘導体およびその医薬用途
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
US7566728B2 (en) Remedy for sleep disturbance
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2005526696A5 (https=)
RU2314809C2 (ru) Способ лечения депрессии соединениями-агонистами дельта-рецепторов
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
US10137113B2 (en) 5-HT4 receptor agonist as a prokinetic agent
CN101663035B (zh) 4-环丙基甲氧基-n-(3,5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途
JP2017516824A5 (https=)
WO2019197670A1 (en) (s)-enantiomeric form of a heterocyclic compound having motivation improving and/or reference memory enhancing activity
RU2005136426A (ru) 5-гидроксииндолы с пиридин-n-оксидными группами и их применение в качестве ингибиторов фосфодиэстеразы 4